Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 53 of 109, showing 5 Applications out of 543 total, starting on record 261, ending on 265

# Protocol No Study Title Investigator(s) & Site(s)

261.

ECCT/15/10/02  
    A non-randomized, open label, single dose, pharmacokinetics, safety and tolerability study of Captopril 50mgs in healthy Kenyan Adults.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
KEMRI centre for clinical Research
 
View

262.

ECCT/24/10/03   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria   
Principal Investigator(s)
1. VIDELIS Nduba
2. Berngards Ogutu
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county)
3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
 
View

263.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
View

264.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
View

265.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View